Villfact 1000 i.m.

LEAFLET INCLUDED IN THE PACKAGING: INFORMATION FOR THE USER

Willfact 500 IU

powder and solvent for solution for injection

Willfact 1000 IU powder and solvent for solution for injection

Willfact 2000 IU powder and solvent for solution for injection

human von Willebrand factor
You should carefully read the contents of this leaflet before using the medicine because it contains important information for the patient.

• You should keep this leaflet, so you can read it again if you need to.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including those not listed in this leaflet, please inform your doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Willfact and what is it used for
• 2. Important information before using Willfact
• 3. How to use Willfact
• 4. Possible side effects
• 5. How to store Willfact
• 6. Contents of the pack and other information

1. What is Willfact and what is it used for

Willfact is made from human plasma (the liquid part of the blood) and contains the active substance human von Willebrand factor (vWF).
vWF is involved in blood clotting. Lack of this factor, as in von Willebrand disease, means that blood does not clot as quickly as it should, resulting in an increased tendency to bleed. Replacing vWF with Willfact temporarily corrects the blood clotting mechanism.
Willfact is indicated for the prevention of bleeding associated with surgical procedures and other bleeding, as well as treatment in patients with von Willebrand disease, if treatment with only desmopressin (DDAVP) is ineffective or contraindicated.
Willfact can be used in all age groups.
Willfact should not be used to treat hemophilia A.

2. Important information before using Willfact

When not to use Willfact

• If you are allergic to human von Willebrand factor or any of the other ingredients of this medicine (listed in section 6).
• If you have been diagnosed with hemophilia A.

Warnings and precautions

Treatment with Willfact should always be monitored by a doctorexperienced in the treatment of bleeding disorders.
If you have severe bleeding and blood tests confirm a decrease in factor VIII, you will receive a factor VIII concentrate and a vWF preparation within the first 12 hours.
Allergic reactions
Allergic hypersensitivity reactionsmay occur, similar to those after administration of other protein-based intravenous drugs derived from human blood or plasma.
You will be monitored during injection to detect early signs of hypersensitivity.
These include rash (hives or generalized urticaria), feeling of pressure in the chest, wheezing, decreased blood pressure (hypotension), and severe allergic reactions (anaphylaxis).
Your doctor will inform you about warning signs of an allergic reaction.
If you experience any objective or subjective signs of hypersensitivity, treatment should be discontinued and medical help sought immediately.
Viral safety
When manufacturing drugs from human blood or plasma, certain measures are taken to prevent the transmission of infections to patients. These include:

• careful selection of blood and plasma donors, allowing the exclusion of individuals at risk of infection,
• testing of each donated batch and plasma pool for the presence of viruses/infections,
• introduction of steps in the processing of blood or plasma that allow inactivation or removal of viruses.

Despite these measures, when administering drugs produced from human blood or plasma, it is not possible to completely rule out the possibility of transmitting an infection. This also applies to unknown or newly emerging viruses or other types of infections.
The measures taken are considered effective against enveloped viruses, such as human immunodeficiency virus (HIV, which causes AIDS), hepatitis B virus, and hepatitis C virus.
The measures taken have limited value against non-enveloped viruses, such as hepatitis A virus and parvovirus B19. Parvovirus B19 infection can be serious in pregnant women (as there is a risk of infecting the unborn child) and patients with weakened immune systems or certain types of anemia (e.g., sickle cell anemia or hemolytic anemia).
Vaccinations
Your doctor may recommend that you receive vaccinations against hepatitis A and B if you regularly/repeatedly receive human von Willebrand factor derived from plasma.
Recording the batch number
It is strongly recommended that when administering each dose of Willfact, the patient's name and batch number of the medicine be recorded to document which batches of the medicine were administered.

Willfact and other medicines

Tell your doctor or pharmacist about all the medicines you are taking, have recently taken, or might take.

Pregnancy and breastfeeding

Willfact can be used in pregnant or breastfeeding women only if clearly necessary.
No controlled clinical trials have been conducted to assess the safety of Willfact in pregnant or breastfeeding women, and animal studies are insufficient to confirm safety in terms of fertility, pregnancy, and child development during pregnancy and after birth.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor or pharmacist for advice before using this medicine.

Driving and using machines

No effects on the ability to drive or use machines have been observed.

Willfact contains sodium

One vial of 5 ml (500 IU) of Willfact contains 0.15 mmol (3.4 mg) of sodium.
This corresponds to 0.17% of the recommended maximum daily intake of sodium for an adult.
One vial of 10 ml (1000 IU) of Willfact contains 0.3 mmol (6.9 mg) of sodium.
This corresponds to 0.35% of the recommended maximum daily intake of sodium for an adult.
One vial of 20 ml (2000 IU) of Willfact contains 0.6 mmol (13.8 mg) of sodium.
This corresponds to 0.69% of the recommended maximum daily intake of sodium for an adult.

3. How to use Willfact

Treatment should be initiated and monitored by a doctor experienced in the treatment of bleeding disorders.
If your doctor decides that you can administer the medicine at home, they will instruct you accordingly.

Dosage

This medicine should always be used exactly as your doctor has told you.
In case of doubt, consult your doctor.
It is recommended that Willfact be administered by a doctor or nurse. However, if you have been given Willfact to use at home, your doctor will ensure that you are informed about how to perform the injection and the correct dose. You should follow the doctor's instructions and ask for help if you have problems using the syringe. The syringe can only be used by a trained person.
Your doctor will calculate the correct dose of Willfact (expressed in international units - IU).
The dose depends on:

• body weight,
• site of bleeding,
• severity of bleeding,
• patient's clinical condition,
• necessity of surgery,
• activity of vWF in the blood after surgery,
• severity of the disease.

The dose is between 40-80 IU/kg body weight.
Your doctor will recommend blood tests to check:

• factor VIII (FVIII:C) levels,
• von Willebrand factor (vWF:RCo) levels,
• presence of inhibitors,
• early signs of thrombosis - in patients at risk of such complications.

Based on the results of these tests, your doctor may adjust the frequency of injections and the dose administered.
In some cases, it may be necessary to use a factor VIII preparation (another coagulation protein) in addition to Willfact to allow for faster treatment or prevention of bleeding (in emergency situations or in the case of acute bleeding).
Willfact can also be used for long-term prophylaxis, in which case the dose is also determined individually. Administering Willfact at a dose of 40-60 IU/kg body weight 2-3 times a week reduces the number of bleeding episodes.
If you think that Willfact is too strong or too weak, talk to your doctor.

Use in children and adolescents

Dosing in children and adolescents is based on body weight. In some cases, especially in younger patients (under 6 years), higher doses (up to 100 IU/kg body weight) may be necessary.

Method of administration

Detailed instructions for reconstitution and administration of the medicinal product are provided at the end of the leaflet.

Overdose of Willfact

No symptoms of overdose with Willfact have been reported, but in the event of administration of a large amount, the risk of thrombosis cannot be ruled out.

Missed dose of Willfact

If you miss a dose of Willfact, consult your doctor.
Do not take a double dose to make up for a missed dose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You should contact your doctor immediately in the following cases:

• Occurrence of hypersensitivity or allergic reactions (observed not very often, may affect up to 1 in 100 patients). In some cases, such reactions may develop into a severe allergic reaction (anaphylaxis), including anaphylactic shock (observed with unknown frequency).

Warning signs of an allergic reaction include:

• difficulty breathing and swallowing,
• wheezing,
• feeling of pressure in the chest,
• rapid heartbeat,
• decreased blood pressure,
• fainting,
• extreme fatigue,
• anxiety, nervousness,
• headache,
• chills, feeling of cold,
• flushes,
• swelling of various parts of the body,
• skin rash, generalized urticaria,
• feeling of burning and stinging at the injection site,
• tingling,
• vomiting,
• nausea.

If you experience any of these symptoms, stop treatment immediately and inform your doctorto initiate appropriate treatment, depending on the type and severity of the reaction.

• Decreased effectiveness of the medicine (lack of bleeding control). This may be due to inhibition of von Willebrand factor (observed with unknown frequency).

In patients with von Willebrand disease, especially type 3, it is possible for proteins that neutralize the action of vWF to develop. Such proteins are called neutralizing antibodies or inhibitors. Patients treated with vWF should be closely monitored by their doctor for the development of inhibitors through appropriate clinical observation and laboratory tests. If inhibitors are present, this condition may manifest as an inadequate clinical response. It may also co-occur with severe allergic reactions.

• Signs of circulatory disorders in the limbs (e.g., cold and pale limbs) or vital organs (e.g., severe chest pain). This may be due to the formation of blood clots in blood vessels (observed with unknown frequency).

There is a risk of blood clots (thrombosis), especially in patients at risk. After correcting the von Willebrand factor deficiency, patients should be monitored for early signs of thrombosis or disseminated intravascular coagulation and receive anti-thrombotic treatment in situations where the risk of thrombosis is increased (after surgery, in bedridden patients, in patients with a deficiency of a coagulation inhibitor or fibrinolytic enzyme).
If you are taking vWF preparations containing FVIII, the risk of thrombosis may be higher due to persistently elevated FVIII levels in the blood.
The following side effects are common(may affect up to 1 in 10 patients):

• reactions at the injection site.

The following side effects are uncommon(may affect up to 1 in 100 patients):

• dizziness,
• paresthesia, numbness,
• flushes,
• itching,
• feeling of pressure in the chest,
• chills, feeling of cold.

The following side effects have been reported with an unknown frequency:

• fever.

Reporting side effects

If you experience any side effects, including those not listed in this leaflet, please inform your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.

5. How to store Willfact

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the vial label and carton.
Do not store above 25°C. Store in the original package to protect from light.
Do not freeze.
To maintain sterility, the product should be used immediately after reconstitution. However, chemical and physical stability has been demonstrated for 24 hours at 25°C.
Do not use this medicine if you notice turbidity or solid particles in the solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

What Willfact contains

Active substanceis human von Willebrand factor (500 IU, 1000 IU, 2000 IU) expressed in international units of ristocetin cofactor activity (vWF:RCo).
After reconstitution with 5 ml (500 IU), 10 ml (1000 IU), or 20 ml (2000 IU) of water for injection, one vial contains approximately 100 IU/ml of human von Willebrand factor.
Before adding albumin, the specific activity of the solution is at least 60 IU vWF:RCo per 1 mg of total protein.
Other ingredients:
Powder: human albumin, arginine hydrochloride, glycine, sodium citrate, and calcium chloride dihydrate.
Solvent: water for injection.

What Willfact looks like and contents of the pack

Willfact is provided as a white or pale yellow powder or brittle solid and a clear, colorless solvent for solution for injection after reconstitution using a transfer system.
Willfact is available in pack sizes of 500 IU/5 ml, 1000 IU/10 ml, 2000 IU/20 ml.
The reconstituted solution should be clear or slightly opalescent, colorless or slightly yellow.

Marketing authorization holder and manufacturer

LFB-BIOMEDICAMENTS
3, avenue des Tropiques,
ZA de Courtaboeuf,
91940 LES Ulis,
FRANCE
pharmacovigilance@lfb.fr

Manufacturers

LFB-BIOMEDICAMENTS
3, avenue des Tropiques,
ZA de Courtaboeuf,
91940 LES Ulis,
FRANCE
LFB-BIOMEDICAMENTS
59 Rue de Trévise
59000 LILLE
FRANCE

This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Austria
Willfact
Czech Republic
WILLFACT
Denmark
Willfact
Spain
Willfact
Germany
WILLFACT
Norway
Willfact
Poland
Willfact
Slovakia
Willfact
Sweden
Willfact
Hungary
Willfact
United Kingdom (Northern Ireland)
Willfact

Date of last revision of the leaflet:

• 01.2024 ________________________________________________________________________________________

INSTRUCTIONS FOR USE:

Dosage

Generally, administration of 1 IU/kg body weight of von Willebrand factor increases the activity of circulating vWF:RCo by approximately 0.02 IU/ml (2%).
Aim to achieve vWF:RCo levels of >0.6 IU/ml (60%) and FVIII:C levels of >0.4 IU/ml (40%).
Hemostasis is uncertain until the coagulant activity of factor VIII (FVIII:C) reaches 0.4 IU/ml (40%). Administration of von Willebrand factor alone does not result in maximum increase in FVIII:C activity for at least 6-12 hours. It is not sufficient for immediate normalization of FVIII:C activity. Therefore, if the initial FVIII:C activity is below the critical value and rapid correction of hemostasis is necessary - as in the case of bleeding, severe trauma, or emergency surgery - factor VIII should be administered with the first dose of von Willebrand factor to achieve hemostatic levels of FVIII:C in the blood.

• Initiation of treatment: The first dose of Willfact is 40-80 IU/kg body weight for the treatment of bleeding or trauma. It is administered in combination with the required amount of factor VIII preparation, calculated based on the initial FVIII:C activity in the patient's blood, to achieve the desired FVIII:C activity in the blood, immediately before surgery or as soon as possible after the start of a bleeding episode or severe trauma. For surgery, the first injection should be given 1 hour before the procedure. An initial dose of 80 IU/kg body weight of Willfact may be necessary, especially in patients with type 3 von Willebrand disease, where maintaining adequate activity may require higher doses than in other types of vWD.

In the case of planned surgery, the first injection of Willfact should be given 12-24 hours before the procedure, and the second injection - immediately before the procedure. In such cases, concurrent administration of factor VIII preparation is not necessary, as the endogenous FVIII:C level usually reaches the critical value of 0.4 IU/ml (40%) before the procedure. However, this should be confirmed in each patient.

• Subsequent injections: If necessary, treatment with Willfact alone should be continued at a dose of 40-80 IU/kg body weight per day in 1 or 2 injections per day for one to several days. The dose and frequency of injections should always be adjusted according to the type of procedure, the patient's clinical and biological condition (vWF:RCo and FVIII:C), and the type and severity of the bleeding episode.
• Long-term prophylaxis: Willfact can be administered for long-term prophylaxis at a dose adjusted individually for each patient. Willfact at a dose of 40-60 IU/kg body weight administered 2-3 times a week reduces the number of bleeding episodes.
• Ambulatory treatment: With the doctor's consent, especially in the case of minor or moderate bleeding or long-term prophylaxis of bleeding, home treatment can be initiated.

Children and adolescents
The dose for each indication is based on body weight. The dose and duration of treatment should be adjusted according to the patient's clinical condition and vWF:RCo and FVIII:C levels in the blood.

• Initiation of treatment
• In children under 6 years of age, the initial dose may be determined based on the patient's incremental recovery (IR) or, if IR data are not available, an initial dose of 60-100 IU/kg body weight may be necessary to increase the patient's vWF:RCo level to 100 IU/dl.
• In children over 6 years of age and adolescents, dosing is the same as in adult patients.
• Subsequent injections: In children and adolescents, subsequent doses should be determined individually based on the patient's clinical condition and vWF:RCo level, and adjusted according to the clinical response.

Scheduled surgery

• In children under 6 years of age, a second dose can be given 30 minutes before surgery after the first dose administered 12-24 hours before the procedure.
• In children over 6 years of age and adolescents, dosing is the same as in adult patients.
• Prophylaxis: In children and adolescents, the dose and frequency of re-administration should be determined individually based on the incremental recovery and vWF:RCo level in the patient, and adjusted according to the clinical response.

Method and route of administration

Intravenous administration
Reconstitution

Current aseptic technique guidelines should be followed. The Mix2Vial transfer system is for use only with this product and is intended for reconstitution only, as described below. The system is not intended for administration of the product to the patient.

Warm both vials (powder and solvent) to a temperature not exceeding 25°C. Remove the protective cap from the vial with the solvent (water for injection) and from the vial with the powder. Disinfect the surfaces of both stoppers.

Remove the cap from the packaging containing the Mix2Vial connector. Without removing the connector from its packaging, attach the blue end of the Mix2Vial connector to the stopper of the vial with the solvent. Remove and discard the packaging of the connector. Be careful not to touch the exposed part of the connector. Invert the vial with the solvent and attached connector and attach it to the vial with the powder using the transparent part of the connector. The solvent will flow into the vial with the powder. Hold the system and gently mix by rotating until the powder is completely dissolved. Then, holding one hand on the part of the connector on the side of the vial with the reconstituted product and the other hand on the part of the connector on the side of the vial with the solvent, unscrew the Mix2Vial connector to separate the vials.

The powder should dissolve in less than 5 minutes, usually instantly.
The resulting solution should be clear or slightly opalescent, colorless or slightly yellow. Before administration, the reconstituted product should be visually inspected for particulate matter and discoloration.
Do not use a cloudy or precipitated solution.
Do not mix with other medicines.
Do not dilute the reconstituted product.
Administration

Hold the vial with the reconstituted product vertically while attaching a sterile syringe to the Mix2Vial connector. Then, slowly draw the product into the syringe. After transferring the product to the syringe, holding the syringe firmly (with the plunger facing down), unscrew the Mix2Vial connector and replace it with a needle for intravenous injection or a butterfly needle. Remove air from the syringe, disinfect the skin, and insert the needle into a vein. Administer slowly intravenously immediately after reconstitution in a single dose at a rate not exceeding 4 ml/min.

Storage after reconstitution
To maintain sterility, the product should be used immediately after reconstitution. However, chemical and physical stability has been demonstrated for 24 hours at 25°C.
Any unused product or waste material should be disposed of in accordance with local requirements.